StockStory flags Bausch + Lomb earnings decline as risk factor

StockStory analysts describe Bausch + Lomb as a cautious investment due to significant declines in earnings and capital efficiency, identifying specific metrics that fall below their standards for business quality. The independent equity research firm argues that the stock presents limited upside relative to potential downside, citing deteriorating financial trends over the past several years.

The firm notes that Bausch + Lomb shares currently trade at $16.69 per share, a level that has produced a 0.6% return over the past six months. This performance lagged the S&P 500, which gained 9.7% during the same period. StockStory attributes its caution primarily to a sharp drop in full-year earnings per share, which fell 93.7% over the last four years, equivalent to an annual decline of 18%. The analysts state that they generally advise readers to avoid companies with falling revenue and earnings, as such trends may indicate shifting secular preferences. They warn that Bausch + Lomb’s low margin of safety could expose the stock to large price drops if market conditions worsen.

A second concern centers on the company’s free cash flow. StockStory emphasizes that cash generation is more critical than accounting profits for paying bills. The firm reports that Bausch + Lomb’s free cash flow margin dropped by 8.4 percentage points over the last five years, reaching 2.6% for the trailing 12 months. While margins may have ticked up recently, the analysts suggest shareholders are likely hoping for a return to historical levels. They caution that any negative movement in this metric is undesirable given the company’s already low cash conversion, noting that a return to longer-term trends could signal a more capital-intensive business model.

The third factor is capital efficiency, measured by return on invested capital (ROIC). StockStory explains that ROIC shows how much operating profit a company generates compared to the debt and equity it has raised. Bausch + Lomb’s five-year average ROIC was 1.5%, which the firm notes is lower than the typical cost of capital for healthcare companies. This suggests the company has historically done a mediocre job investing in profitable growth initiatives.

Despite these concerns, StockStory describes Bausch + Lomb’s current valuation as fair, with the stock trading at $16.69 per share. However, the firm concludes that the potential upside is not substantial enough to offset the risks. The analysts express confidence that better investment opportunities exist in the current market and direct readers toward a top digital advertising platform riding the creator economy as an alternative.